We are live on
!
Find out more
FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
1-Year Est. Return
44.84%
This Fund
S&P 500
This Quarter
Est. Return
-4.93%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$301M
AUM Growth
+$14.4M
(+5%)
Cap. Flow
+$42.7M
Cap. Flow
% of AUM
14.19%
Top 10 Holdings %
Top 10 Hldgs %
99.73%
Holding
15
New
4
Increased
3
Reduced
–
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$11.8M |
| 2 |
ALDR
Alder Biopharmaceuticals
ALDR
|
+$9.29M |
| 3 |
AIMT
Aimmune Therapeutics
AIMT
|
+$7.73M |
| 4 |
ADAP
Adaptimmune Therapeutics
ADAP
|
+$3.5M |
| 5 |
Ardelyx
ARDX
|
+$998K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JUNO
Juno Therapeutics, Inc.
JUNO
|
+$3.88M |
| 2 |
uniQure
QURE
|
+$2.14M |
| 3 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
| $106M | 35.15% |
3,319,945
+219,799
| +7% | +$7.73M |
|
|
AERI
2
DELISTED
Aerie Pharmaceuticals
AERI
| $90.7M | 30.19% |
1,672,714
| – | – |
|
|
EPZM
3
DELISTED
Epizyme, Inc
EPZM
| $27.7M | 9.2% |
1,558,108
| – | – |
|
|
4
Insmed
INSM
$23.5B
| $21.8M | 7.25% |
967,636
+448,991
| +87% | +$11.8M |
|
|
ALDR
5
DELISTED
Alder Biopharmaceuticals
ALDR
| $21.4M | 7.12% |
1,686,220
+642,388
| +62% | +$9.29M |
|
|
AIMT
6
PUT
DELISTED
Aimmune Therapeutics
AIMT
| $13.9M | 4.62% |
+437,900
| New | +$15.4M |
|
|
XLRN
7
DELISTED
Acceleron Pharma
XLRN
| $9.57M | 3.18% |
244,756
| – | – |
|
|
ADAP
8
DELISTED
Adaptimmune Therapeutics
ADAP
| $4.49M | 1.49% |
+400,000
| New | +$3.5M |
|
9
Denali Therapeutics
DNLI
$3.7B
| $3.7M | 1.23% |
250,000
| – | – |
|
|
SGMO
10
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $877K | 0.29% |
+46,138
| New | +$986K |
|
|
11
Ardelyx
ARDX
$1.28B
| $808K | 0.27% |
+159,967
| New | +$998K |
|
|
12
uniQure
QURE
$2.77B
| – | – |
-109,350
| Closed | -$2.14M |
|
|
ALDR
13
CALL
DELISTED
Alder Biopharmaceuticals
ALDR
| – | – |
-24,000
| Closed | -$40K |
|
|
LOXO
14
DELISTED
Loxo Oncology, Inc
LOXO
| – | – |
-11,900
| Closed | -$1M |
|
|
JUNO
15
DELISTED
Juno Therapeutics, Inc.
JUNO
| – | – |
-85,000
| Closed | -$3.88M |
|
Similar funds
AG
SAM
AC
QI
TAAM
NAM
MSKCC
BRC
Foresite Capital Management II's Q1 2018 Portfolio in Review
As of Q1 2018, Foresite Capital Management II held 15 positions worth $301M, up 5% from $286M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Foresite Capital Management II deployed $42.7M of net new capital in Q1 2018, opening 4 new positions and adding to 3 existing holdings. Its largest new stake was Adaptimmune Therapeutics: 400,000 shares worth $4.49M.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, up from 23% a quarter earlier.
On the sell side, the most notable exit was Juno Therapeutics, Inc., an estimated $3.88M sold.
- Foresite Capital Management II's largest Q1 2018 buy was Adaptimmune Therapeutics: 400,000 shares worth $4.49M.
- Foresite Capital Management II added most to Insmed in Q1 2018, an estimated $11.8M increase.
- Foresite Capital Management II fully exited Juno Therapeutics, Inc. in Q1 2018, selling an estimated $3.88M.
- Foresite Capital Management II's ten largest holdings make up 100% of its $301M portfolio in Q1 2018.
- Foresite Capital Management II opened 4 new positions and closed 4 in Q1 2018.
- Foresite Capital Management II's portfolio value rose 5% quarter-over-quarter to $301M.
Based on Foresite Capital Management II's 13F filing for Q1 2018, filed 15 May 2018.